Significant Stock Recovery of UnitedHealth and Humana Amid Medicare Advantage Growth
UnitedHealth Group's stock saw a significant boost following its robust first-quarter 2026 earnings, where adjusted earnings per share reached $7.23, surpassing the anticipated $6.57. The company has also revised its 2026 earnings forecast to exceed $18.25 per share. UnitedHealth’s diversified operations, particularly through its Optum unit, have effectively mitigated potential volatility in the Medicare Advantage market. This strategic approach contributed to an expansion of operating margins to 7%.
Meanwhile, Humana's stock has also appreciated as the Medicare Advantage market stabilizes, although its reliance on this segment entails certain risks. With an expected 25% growth in individual Medicare Advantage enrollment and significant dependency on Star Ratings, Humana's exposure to regulatory compliance requirements is more pronounced than UnitedHealth's.
Both UnitedHealth and Humana have demonstrated noteworthy recovery in the stock market in 2026, with their stocks increasing by 36% and 34%, respectively, since the end of March. This upward trend follows substantial declines in late 2025. Year-to-date, UnitedHealth's shares have risen by 12%, outpacing Humana, which has encountered a 9% year-to-date decline.
UnitedHealth's recent quarterly report highlighted an improved medical cost ratio of 84%, compared to 85% the previous year, alongside a confirmed revenue target surpassing $439 billion. CEO Stephen Hemsley highlighted the company's dedication to modernizing healthcare, positively influencing market sentiment.
Humana's stock recovery began post its fourth-quarter 2025 earnings release, which offered an adjusted 2025 earnings per share of $17.14 and lowered 2026 guidance, primarily affected by Star Ratings. However, CEO Jim Rechtin remains confident in the company's strategy and Medicare Advantage membership growth. The contrast between the two giants lies in their diversification strategies. UnitedHealth benefits from Optum’s wide-ranging portfolio that includes pharmacy benefits and healthcare services, offering more stable earnings.
Sector-wide improvements, such as reduced hospitalization rates and an average 2% increase in 2027 Medicare Advantage payments, are encouraging both companies. Humana is set to report its first-quarter 2026 results soon, with expectations of a favorable outcome based on management's guidance. Nonetheless, both insurers face persistent challenges from potential regulatory changes in Medicare Advantage rates and drug pricing, as well as possible increases in medical costs. These elements may impact their stock performance, prompting investors to exercise caution.